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Regulation of the immune system is vital to efficient functioning. Key factors in 
this regulation are the two specific elements in the system, the immunogens and the 
antigen-specific antibody molecules and  receptors. Administration  of antibodies  to 
the immune system in vivo may have quite paradoxica! consequences depending on 
the circumstances of administration.  Initially, it was  found that, whereas  immune 
serum would normally reduce the humoral response against  the relevant antigen if 
administered early enough  after immunization  (1,  2),  administration  of antibodies 
could, with regard to induction of delayed-type hypersensitivity reactions, frequently 
lead  to an  enhanced  induction  of this  form of immune  reaction  (3)  Dissection of 
antibodies into IgM and IgG classes subsequently revealed that IgM would normally 
potentiate the immune responses against  low doses of relevant antigen  (4), whereas 
antibodies of IgG class would normally act in a  selective, inhibitory manner  (4, 5). 
The ability of IgM antibodies to exert their immunostimulatory capacity for humoral 
antibody  production  is  now  known  to  require  immunocompetent  T  lymphocytes 
(6-8), and  it  may well be that  the acute potentiating power of administered  IgM 
antibodies is exerted at the level of T  cell help for antibody production. 
The capacity of the IgM antibodies to potentiate antibody production has been 
reported to occur through several mechanisms.  One way through which IgM  anti- 
bodies  may  function  has  been  reported  to  involve idiotypic determinants,  as  the 
injection of IgM  antibodies alone caused induction of synthesis of IgM  antibodies 
with the same specificity (9).  The same group of workers  (8)  have also found that 
some IgM antibodies may also have an inherent capacity to induce polyclonal B cell 
activation in vivo. 
Other  studies  emphasize  the  features  of the  constant  regions.  IgM  antibodies 
reactive with  one antigenic  determinant  on  an  erythrocyte can  thus  enhance  the 
humoral response against an entirely unrelated epitope if the latter is present on the 
same erythrocyte during the potentiation process  (10-12).  In  the present  study we 
have used monoclonal or polyclonal IgM anti-sheep erythrocyte (SRBC) 1 antibodies 
with defined differences in their antigen-combining specificity tQ analyze the condi- 
tions under which IgM antibodies may potentiate the humoral antibody response in 
Abbreviations  used in  this paper: BSS,  balanced salt  solution;  DMEM,  Dulbecco's modified essential 
medium; GRBC,  goat  erythrocytes;  HRBC,  horse erythrocytes;  PBS,  phosphate-buffered saline;  PFC, 
plaque forming cells; SRBC, sheep erythrocytes. 
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acute systems, that is, when the time of inoculation between antibodies and antigen 
is a  matter of minutes. Our results do clearly show that binding of IgM antibodies to 
one group of determinants on an erythrocyte will lead to enhanced reactivity against 
other determinants present on the same erythrocyte (RBC). 
We  failed  to  find  any  evidence of an  inherent ability of either  monoclonal or 
polyclonal IgM antibodies to induce antibody production of the same specificity in 
the absence of administered antigen. Nor did we find any evidence that the specificity 
of the  administered IgM  antibodies would be reflected  as  an increased fraction of 
plaque-forming cells (PFC) with similar fine antigen-binding  specificity appearing in 
these acute, potentiating systems. The implications of these results will be discussed. 
Materials and Methods 
Animals.  Unless otherwise indicated, data were obtained with CBA/H mice, aged  12-16 
wk,  from the breeding facilities  of Anticimex, Stockholm, Sweden, or from our own animal 
colony. AKR mice 10-18 wk old from our breeding were used in one experiment. 
Monoclonal IgM.  IgM-anti-SRBC antibody-secreting hybridomas were  obtained from  a 
fusion between spleen cells from a CBA/H mouse immunized with 4 ×  10  s SRBC 3 d before 
fusion, and the BALB/c nonsecreting  hybridoma line Sp 2/0 (13). Fusion was done as described 
(14). In brief, the two cell types were mixed with polyethylene glycol, and seeded into microtiter 
dishes  in selective  hypoxanthine, aminopterin, and thymidine (HAT) medium. Clones with 
ability to lyse SRBC in presence of complement were selected,  recloned by limiting dilution, 
and kept growing in Dulbecco's modified essential medium (DMEM) containing 5% fetal calf 
serum. Supernatants were collected, and the antibody class was  determined by class-specific 
antisera and also by Sepharose CL-6B (Pharmacia Inc., Uppsala) fractionaton, testing if the 
hemolytic capacity eluted in the  19  S  or  7 S  peak.  Before  using these  antibodies in some 
experiments they were fractionated on a Sepharose CL-6B column. The 19 S peak containing 
the lyric activity was concentrated by negative pressure,  dialyzed against phosphate-buffered 
saline (PBS), and stored at -20°C. In other experiments culture supernatants were used directly 
or after ammonium sulphate precipitation followed by extensive dialysis. All hybridomas used 
in the present study were of IgM type. 
Serum lgM.  CBA/H mice were injected with 4 ×  10  s SRBC intraperitoneally and bled on 
day 5. The immune serum was fractionated on a Sepharose CL-6B column, concentrated, and 
stored in the same way as the monoclonal antibodies. 
Antigens.  Goat  and  horse  erythrocytes  (GRBC  and  HRBC)  were  purchased  from  the 
National Veterinary Institute, Stockholm, Sweden, and SRBC were donated by the Department 
of Pathology, University of Uppsala. The blood was stored in sterile Alsevers solution at 4°C. 
SRBC  Surface Glycoprotein Preparation.  Glycoprotein from  the  membranes of  SRBC  was 
prepared as described by Hamaguchi and Cleve (15). In brief, the cells were hemolyzed and 
centrifuged. The  ghosts  obtained by  this  procedure  were  mechanically homogenized and 
subsequently diluted 1:9 in a  CHCI3/CHaOH mixture and centrifuged at  1,500 rpm for  10 
min. The supernatant was  removed and further centrifuged at  100,000 g  for  60  min. This 
supernatant was clear, contained glycoproteins, and was used in the inhibition assay. 
Antibody Titrations.  The reciprocal of the highest antibody dilution able to completely lyse 
(in  presence of guinea pig complement diluted  1:200) or  agglutinate a  0.25% solution of 
erythrocytes (all dilutions in balanced salt solution [BSS]) after  1 h  incubation at 37°C was 
defined as the antibody titer. 
Inhibition Assay.  Hemolytic assays were performed as described above but a constant amount 
of SRBC membrane glycoprotein preparation was also added to each antibody dilution. Only 
BSS was added to controls. The titers were defined as for hemolysis assay described above. 
Absorption Studies.  Twofold serial dilutions of  100 #1  of each  supernatant were  made in 
microtiter plates.  Packed RBC were added so that a final erythrocyte concentration of 12.5% 
was  obtained in each  well.  The plates were  incubated for  1 h  at  room  temperature while 
shaking gently. RBC were then spun down at  1,500 g for  10 min. 50 #1 of the supernatant in 996  ENHANCEMENT OF THE SHEEP  ERYTHROCYTE  RESPONSE IN  MICE 
each well was transferred to individual wells in a new plate and tested in a hemolysis assay, as 
described above, by adding guinea pig complement and RBC to each well. 
Immunizations.  Unless otherwise indicated, groups of four to five mice were given 0.1 ml of 
the antibody preparations in their tail veins 1-2 h before the intravenous injection of 4 ×  105 
RBC in 0.1 ml PBS. Normally the mice were killed 5 d later and their spleens tested in plaque 
assays. Control groups received 0.1  ml of PBS or cell culture medium, containing the same 
amount of fetal calf serum as the injected IgM-containing  supernatants, before the erythrocytes. 
Plaque Assays.  A modified version of the Jerne plaque assay (16) was used: 25 btl of a 25% 
RBC suspension, 100/~1 of an appropriately diluted lymphocyte suspension, and 25/zl guinea 
pig complement diluted 1:4 were added to 0.5% agar at 45°C (300/zl Difco agar containing 
0.75 mg/ml DEAE dextran [Pharmacia]), mixed, and plated on a plastic petri dish (Diam 9 
cm). All dilutions were made in BSS. The plates were incubated for 2 h at 37°C. 
For measuring indirect plaques 25/d of a rabbit-anti-mouse  immunoglobulin  antiserum was 
used as developing antiserum. The number of indirect plaques is given after the direct PFC 
number has been subtracted. The plaques were always counted "blindly". 
Calculations.  The plaque numbers are given as the X°log  and geometrical mean :t: standard 
error of the mean of groups of four to five mice. The significance  of the differences between the 
groups was tested by Students t test  (17). P values >0.2 were designated not significant in the 
tables. 
Results 
Characteristics of the Monoclonal IgM-Anti-SRBC Antibodies.  Three CBA anti-SRBC 
IgM monoclonals were obtained from the same fusion. They were tested for reactivity 
against  SRBC,  HRBC,  and  GRBC  using hemagglutination or  hemolytic  assays. 
Furthermore, the antibodies were tested  for reactivity against surface glycoproteins 
on  SRBC  using a  hemolysis  inhibition assay.  The  results  obtained are  shown  in 
Table I and demonstrate that the three monoclonal antibodies have different antigen- 
binding specificities. Unlike the other two,  16-3 does not react with GRBC, and 7-3 
is  the  only monoclonal with  reactivity towards  SRBC-derived  glycoproteins. The 
finding that  16-3  is  unreactive with  GRBC  using hemagglutination or  hemolytic 
assays was then further substantiated using absorption experiments as summarized in 
Table II. Here we also included HRBC as another antigen to be tested by absorption. 
HRBC constitute an antigen normally claimed to only cross-react with SRBC at the 
T  but not the B cell level to any significant degree (18,  19). In line with this we failed 
TABLE  I 
The Antigen-binding Specificity of the Monoclonal Antibodies 
Antibody 
Anti-SRBC  Anti-GRBC  Anti-HRBC 
Hit*  Hat~  Hat  Hat  Hit  Hat 
Anti-SRBC§ 
Hit 
No glyco-  Glyco- 
protein 
protein  added 
7-3  4096  1024  4096  <4  <4  <4  2560  <5 
10-21  1024  <4  2048  <4  <4  <4  320  320 
16-3  4096  512  <4  <4  <4  <4  640  640 
* Reciprocal of hemolytic titer of the antibody preparations. 
Reciprocal of hemagglutination titer of the antibody preparations. 
§ Antibody titrations before and after the addition of a competing antigen (SRBC membrane glycoprotein) 
to the antibody dilutions. These data were obtained with different antibody preparations than those used 
in the first part of this table, thus explaining the difference  in titers. B.  HEYMAN, G.  ANDRIGHETTO,  AND H.  WIGZELL 
TABLE II A 
Antibody 16-3 is Unable Both to Bind to and to Lyse GRBC 
997 
Anti-GRBC hemolysis* 
Antibody 
Anti-SRBC hemolysis* 
Ab-  Percent  Ab-  Percent  Ab-  Per-  Ab- 
Unab-  sorbed  sorbed  Unab-  sorbed  cent  sorbed  ab-  ab-  sorbed  on  on  sorbed  on  ab-  on  sorbed  sorbed  GRBC  SRBC  GRBC  sorbed SRBC 
Percent 
ab- 
sorbed 
10-21~  512  32  94  32  94  128  32  75  32  75 
50-2~  256  16  94  16  94  64  16  75  8  88 
7-3~  4096  8  99.8  <4  >99.9  4096  8  99.8  <4  >99.9 
16-3~  <4  <4  --  <4  --  4096  4096  0  <4  >99.9 
anti-SRBC§  256  <4  >98  <4  >98  1024  128  88  16  98 
TABLE  II B 
Antibodies 10-21, 50-2,  7-3, and 16-3 Are Unable Both to Bind to and to Lyse HRBC 
Anti-HRBC hemolysis*  Anti-SRBC hemolysis* 
Unab-  Absorbed  Percent  Absorbed on 
Antibody  sorbed  on HRBC  absorbed  Unabsorbed  HRBC 
Percent 
ab- 
sorbed 
10-21~  <4  NT[I  1024  1024  0 
50-2~  <4  NT  1024  1024  0 
7-3~  <4  NT  4096  4096  0 
16-3~  <4  NT  32768  32768  0 
Anti-HRBC¶  256  <4  >98  NT  NT 
* Expressed as reciprocal of hemolytic titer. 
Culture supernatants. 
§ Serum from CBA/H mice immunized with SRBC. 
II Not tested. 
¶ Serum from CBA/H mice immunized with HRBC. 
to absorb away any anti-SRBC activity using HRBC as absorbing agent. Accordingly, 
as judged by binding assays of various kinds, none of our three monoclonals bind to 
HRBC, two out of three react with GRBC and all bind well to SRBC. However, note 
that  10-21  in its reaction with SRBC was distinct from the other two monoclonals in 
its ability to lyse SRBC while failing to agglutinate the same erythrocytes. It is thus 
clear that use of the above monoclonals with their distinct antigen-binding  specificities 
should allow an analysis of the impact of the constant vs.  variable regions of IgM 
antibodies in the enhancement of the immune response against SRBC. 
Equal Ability of Different Monoclonal and Polyclonal IgM-Anti-SRBC Antibodies to Enhance 
Anti-SRBC Antibody  Responses  When Given  Together  with  Low  Doses of SRBC.  Having 
defined the  fine specificity variation of the three  IgM-anti-SRBC monoclonal anti- 
bodies, we next assessed their ability to enhance anti-SRBC antibody responses when 
given with  low doses  of SRBC  in accordance with previous protocols  (4).  Using a 
constant low dose of antigen and varying amounts of antibodies we could demonstrate 
that  all  three  monoclonals and  the  polyclonal anti-SRBC  IgM  serum  antibodies, 
measured by  hemolytic titers,  had  a  similar ability to  potentiate anti-SRBC  PFC 
production (see Fig. 1 for a representative experiment out of three performed). At the 
present  dose  of  4  ×  105  SRBC,  the  optimal  dose  of  antibodies  as  estimated  by 998  ENHANCEMENT  OF THE SHEEP ERYTHROCYTE RESPONSE IN MICE 
Fro.  1.  Dose-response  diagrams of mice given different, Sepharose-purified monoclonal  or serum 
IgM-antibodies with a titer of 20 (t~), 200 ([i), or 2048 (m), or PBS (F-I) before 4 X l0  s SRBC. 
Standard errors are indicated as vertical bars. 
hemolytic titer was reached at dilution  1:200 using 0.1  ml vol for injection.  Higher 
amounts of monoclonal antibodies failed to further increase the enhancement, and in 
most experiments  this was also the case for polyelonal serum IgM-anti-SRBC anti- 
bodies. 
This means that there seemingly exists  an optimal amount of IgM per erythrocyte 
to obtain maximum enhancement of the anti-RBC antibody response. This increase 
as measured by quantity of the response (here numbers of PFC) would seem to be of 
the same magnitude regardless of the fine variations in the antigen-binding area of 
the IgM molecules used for induction of enhancement. Further evidence for optimal 
amounts IgM on the  SRBC being responsible  for the enhancing properties,  rather 
than  numbers  or types of idiotopes present  on the  respective  IgM antibodies,  was 
obtained from experiments comparing the enhancing capacities of monoclonal anti- 
bodies  alone  with  those  of mixtures  of monoclonals of equal  titers  or  the  use  of 
polyclonal IgM anti-SRBC serum  antibodies.  These experiments  as  exemplified  in 
Table III demonstrate equal capacity of monoclonal IgM anti-SRBC when compared 
with  mixtures  of monoclonals or polyclonal serum  IgM antibodies,  to enhance the 
anti-SRBC response induced by low doses of SRBC. No consistent superiority of any 
of these reagents (or mixture of reagents) were thus noted in these assays. 
Kinetics of the  Enhancing Capacity of Monoclonal IgM Anti-SRBC for Anti-SRBC Re- 
sponses.  Reports have been published indicating that IgM antibodies against SRBC 
by themselves may function as polyclonal B cell activators  (8). This required  us to 
include two sets of controls, one to analyze the kinetics of enhancement observed in 
the present system, and another to study the specificity of antibody synthesis induced 
with or without antigen. 
In our analysis of the kinetics of enhancement, we demonstrated that mice tested 
24 h after injection with 4 ×  105 SRBC with or without IgM-anti-SRBC antibodies 
showed background numbers of PFC.  Subsequently, a  clear-cut rise  in  PFC  in  the 
animals receiving antigen plus antibodies was noted when compared with the figures 
obtained in mice receiving SRBC alone (see Fig. 2). IgM~anti-SRBC antibodies could B.  HEYMAN,  G.  ANDRIGHETTO, AND  H.  WIGZELL  999 
TABLE  III 
The Degree of Enhancement by Different Monoclonal Antibodies and Serum IgM in Relation to Antibody 
Concentration and/or Number of Clones 
Injec-  Hlt*  Hat:l:  Injection II  PFC-anti-  P (vs.  P (vs.  P (vs. 
tion I  SRBC§  control)  mix)  IgM) 
Experiment 1  7-311  128  16  4~ ×  105 SRBC  4.99:1:0.024  <0.001  NS¶ 
(96.942) 
10-2111  128  <4  4 ×  105 SRBC  5.04 ± 0.087  <0.005  NS 
(111.488) 
16-3[I  128  16  4 ×  105 SRBC  4.98 ± 0.060  <0.005  NS 
(95.898) 
Mix**  255  32  4 ×  105 SRBC  5.06 ± 0.060  <0.001 
(126.066) 
DMEM  4 x  l05 SRBC  4.13 ± 0.17 
(13.493) 
Experiment 2  10-2111  128  NT:~:~  4 ×  105 SRBC  5.14 -4- 0.043  <0.001 
(138.038) 
16-3[]  128  NT  4 ×  105 SRBC  4.84 ± 0.11  <0.025 
(66.069) 
IgM§§  128  NT  4 ×  105 SRBC  4.85 :t: 0.027  <0.005 
(70.795) 
PBS  4 ×  105 SRBC  4.19 ± 0.16 
(15.488) 
<0.001 
NS 
* Reciprocal of direct hemolytic titer. 
:]: Reciprocal of direct hemagglutination titer. 
§ 1°log PFC/spleen. Figures within brackets equal geometrical mean. 
1[ 19 S fraction of culture supernatants. 
¶ For simplicity, P values >  0.2 are denoted not significant. 
** Equal amounts of the individual monoclonal antibody preparations tested  in this experiment were 
mixed and 0.1 ml of the mixture was injected. 
:~:~ Not tested. 
§§ 19 S fraction of serum from CBA/H mice immunized with SRBC. 
also  be shown to  potentiate the  IgG-anti-SRBC response as  demonstrated  in Table 
IV.  Using a  somewhat  higher  antigen dose  (4  ×  106)  a  significant increase of IgG- 
anti-SRBC PFC was observed in the present IgM potentiated system. 
From  this  we  can  conclude  that  the  enhancement  of antibody synthesis by IgM 
anti-SRBC antibodies is not confused by errors, such as false positive PFC induced by 
the  injected  antibodies passively adsorbed  to  cells,  but  rather  represents  an  active 
increase in the synthesis of anti-SRBC antibodies, including Ig classes of types other 
than the enhancing molecules. The  parallel kinetics of the curves between the  PFC 
values  in  mice  receiving SRBC  alone or  in  addition  anti-SRBC  antibodies would 
indicate an increased efficiency in a  normal step ofanti-SRBC  induction, rather than 
the introduction of some new mechanism. 
Failure of Monoclonal  or Polyclonal  IgM-Anti-SRBC  Antibodies  to  Induce  an  Active  Anti- 
SRBC Response  in the Absence of SRBC.  To  further  analyze the possibility that  IgM- 
anti-SRBC antibodies by themselves may cause production of IgM-anti-SRBC  anti- 
bodies without addition of any antigen (9), we carried out a  very extensive study on 
the possible impact of giving IgM anti-SRBC antibodies alone under varying condi- 
tions. To  make  this  study as broad  as  possible, we  examined our three  monoclonal 
IgM separately, as a  mixture of all three, or tried polyclonal IgM anti-SRBC serum 1000  ENHANCEMENT OF THE  SHEEP  ERYTHROCYTE  RESPONSE  IN  MICE 
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FtG.  2.  Kinetics of the direct PFC response of mice given Sepharose-purified  monoclonal antibody 
10-21 with a hemolytic titer of 256 (m) or PBS (0) followed by 4 ×  105 SRBC. Standard errors are 
indicated as vertical bars. The P value of the difference between control and experimental groups 
was, except on day 1, <0.001. 
TABLE  IV 
IgM also Enhances the Indirect PFC Response Against SRBC 
Direct PFC-  P (vs.  Indirect PFC-  P (vs. con-  Injection I  Hh*  Injection II  anti-SRBC:~  control)  anti-SRBC§  trol) 
7-31[  1024  4 ×  106 SRBC  4.76 zl: 0.035  NS¶  5.49 +_ 0.097  <0.005 
(57.394)  (312.454) 
PBS  4 ×  106 SRBC  4.74 :t: 0.063  4.77 +  0.11 
(54.946)  (59.496) 
* Reciprocal of direct hemolytic titer. 
~°log direct PFC/spleen +  SE; figures within brackets  equal geometrical mean. 
§ l°log indirect PFC/spleen +  SE; figures within brackets equal geometrical mean. 
[[ Ammonium-sulphate-precipitated culture supernatant. 
¶ Not signifiicant (P >  0.2). 
antibodies  as well. A  total  of 21  experiments  of this  kind  were  performed  with  very 
similar,  negative results:  no ability of IgM  anti-SRBC  antibodies  to alone  induce  an 
active  anti-SRBC  response  was  observed.  In  Table  V  we  have  included  three 
experiments  to  represent  the  various  approaches  used  as  to  reagents,  titers  of IgM 
antibodies applied, etc. Table V  includes the only individual group of animals where 
one  might  have  considered  a  positive  effect  at  one  particular  titer  step  of  IgM 
antibodies  (experiment  1,  titer  128),  but  note  that  the  increase  was  very  marginal 
from 57  in the background  to  125  in  the antibody-treated  group.  This,  plus  the  fact 
that  none of the other  20 experiments  showed  even this weak increase  by  IgM  anti- 
SRBC  antibodies,  makes  us  feel confident  that  IgM-anti-SRBC  antibodies  can  not TABLE V 
No Enhancement if SRBC Are Not Injected 
P  (vs, 
Inj I  Hit*  Inj II  PFC-anti-SRBC:~  control) 
Experiment 1  IgM§  1024  0  1.89 +  0.073  NS  H 
(76) 
IgM  512  0  1.82 4- 0.073  NS 
(66) 
IgM  256  0  1.82 4- 0.073  NS 
(66) 
IgM  128  0  2.10 4- 0.062  <0.001 
(125) 
IgM  64  0  1.95 4- 0.11  NS 
(89) 
PBS  0  1.76 4- 0.06 
(57) 
IgM  256  4 x  105 SRBC  5.54 4- 0.072  <0.001 
(122.395) 
PBS  4 ×  105 SRBC  4.31 4- 0.12 
(20.749) 
Experiment 2 
Experiment 3 
Mix¶  8192  0  1.76 +  0.060  NS 
(57) 
Mix  1024  0  2.26 4- 0.14  NS 
(183) 
Mix  512  0  1.99 4- 0.14  NS 
(99) 
Mix  256  0  2.32 4- 0.17  NS 
(210) 
Mix  64  0  1.89 4- 0.12  NS 
(78) 
DMEM  0  2.0 4- 0.23 
(100) 
Mix  1024  4 ×  105 SRBC  3.72 4- 0.20  <0.05 
(5.208) 
DMEM  4 ×  105 SRBC  3.07 
(1.168) 
7-3**  4096  4 ×  105 SRBC  4.27 4- 0.10  <0.1 
(18.460) 
10-21"*  256  4 ×  l0  b SRBC  4.63 4- 0.091  <0.0l 
(42.491) 
16-3"*  8192  4 ×  105 SRBC  4.80 4- 0.057  <0.005 
(62.842) 
DMEM  4 ×  105 SRBC  3.91  4- 0.29 
(5.400) 
7-3**  4096  0  2.27 4- 0.081  NS 
(188) 
10-21"*  256  0  2.28 4- 0.16  NS 
(192) 
16-3"*  8192  0  2.04 4- 0.24  NS 
(110) 
DMEM  0  2.47 4- 0.23  NS 
(298) 
* Reciprocal of hemolytic titer of the antibody preparations. 
:[: a°log PFC/spleen 4- SE; figures within brackets equal geometrical mean. 
§ 19 S fraction of serum from CBA/H mice immunized with SRBC. 
II Not significant (P >  0.2). 
¶ Equal amounts of the three individual monoclonal antibody preparations were mixed, and 0.1 ml of the 
mixture, or a dilution in DMEM, was injected. 
** Culture supernatants. 
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induce  any  further  IgM-anti-SRBC  antibodies  by  themselves  in  the  absence  of 
relevant antigen in the presently studied system. 
The Fine Specificity of the IgM Monoclonal Anti-SRBC Antibodies is Decisive in Allowing the 
Induction of Potentiation of the Anti-SRBC Response, but Does Not Determine the Fine Specificity 
of the Enhanced Antibody Production.  A crucial question in systems studying potentiation 
of antibody  production  by  previous  administration  of antibodies  is  whether  this 
enhancing ability may influence in a  very direct manner the antibody specificity of 
the Ig molecules produced. Whereas it is clear that injection of monoclonal antibodies 
some  days  or  weeks  before  the  actual  challenge  with  antigen  may  lead  to  either 
enhancement or suppression of a particular group of antibodies with similar idiotypes/ 
fine antigen-binding features as the administered antibodies (20-22), confusion exists 
as to whether such an impact is seen in acute potentiation of the type studied in this 
article. On one hand, reports exist indicating that IgM antibodies against one epitope 
on an erythrocyte will nicely potentiate the response against an unrelated epitope if 
present  on the same erythrocyte (10-12).  On  the other hand,  the reports that  IgM 
antibodies may, by themselves, acutely induce an active production of more antibodies 
with the very same specificity (9) would by necessity imply that idiotypic determinants 
may play a  highly decisive role even in the present acute IgM potentiation systems. 
To analyze this question  further we took advantage of the fine specificity variations 
in our three monoclonal IgM antibodies (all binding to SRBC, two binding to GRBC, 
and none reacting with HRBC). 
SRBC  and  GRBC  cross-react  extensively at  both  B  and  T  cell  levels,  whereas 
HRBC  and  SRBC  have some detectable cross-reactions at  the T  lymphocyte level 
but virtually no cross-reactions at the level of humoral antibodies  (18-19).  First, we 
used  GRBC  instead  of SRBC  as the  immunogen with  or without  IgM-anti-SRBC 
monoclonals, and assayed for PFC against both GRBC and SRBC. The results were 
clear cut: the two monoclonal antibodies, which also cross-react with GRBC, worked 
beautifully  as  potentiators  of IgM  PFC  induction  against  GRBC  and  SRBC  (see 
Table VI  for one representative experiment  out  of three).  On  the  other  hand,  the 
monoclonal IgM anti-SRBC antibody  16-3,  which  does not cross-react with GRBC, 
also  failed  to  have  any  impact  in  these  sets  of experiments  when  GRBC  was  the 
immunogen. 
In  contrast,  when  the  same  non-GRBC  cross-reacting  monoclonal  is  used  to 
potentiate the response against SRBC and GRBC now using SRBC as the immuno- 
gen, the "normal" potentiation against both SRBC and GRBC is seen (Table VI). A 
representative experiment showing that the same relative degree of enhancement of 
anti-GRBC  PFC  is  seen,  whether  or  not  we  use  monoclonals  cross-reacting  with 
GRBC together with SRBC as the immunogen, is shown in Table VII. These results 
are thus in direct agreement with the concept that the IgM antibodies potentiate via 
binding to the erythrocytes, thereby alowing other epitopes on the same erythrocyte 
to display enhanced immunogenic properties. 
Further  evidence  supporting  this  concept  was  then  derived  from  studies  using 
HRBC  instead  of GRBC  in  similar  kinds  of experiments.  We  now  investigated 
whether anti-SRBC IgM monoclonals, when given with HRBC alone, SRBC alone, 
or with mixtures of the two erythrocytes, would potentiate the respective anti-HRBC 
and -SRBC responses. While interpreting the results from these studies,  it should be 
remembered that  none of the  monoclonal  IgM anti-SRBC  express  any binding  to B.  HEYMAN,  G.  ANDRIGHETTO,  AND  H.  WIGZELL  1003 
TABLE  VI 
Failure of Monoclonal Anti-SRBC-Antibodies which Are Non-Crossreactive with GRBC to Potentiate the 
Anti-GRBC  PFC Response When GRBC Is the Immunogen 
PFC-anti-  P (vs.  P (vs. 
Inj I  Hlt*  Inj II  GRBC:[:  control)  PFC-anti-SRBC  control) 
16-3§[  I  1024  4 ×  l0  s GRBC  4.04 ±  0.18  NS¶  3.37 ~  0.12  NS 
(8.787)  (1.842) 
7-3§  2048  4 ×  l0  s GRBC  4.52 :l: 0.13  <0.005  3.99 ±  0.18  <0.025 
(32.950)  (9.883) 
10-21§  512  4 ×  l0  s GRBC  4.34 :lz 0.13  <0.01  3.78 :t: 0.12  <0.05 
(21.955)  (5.976) 
DMEM  4x  10s GRBC  3.74:t:0.13  3.23±0.17 
(5.529)  (1.701) 
16-3§11  1024  4 ×  l0  s SRBC  4.23 +  0.085  <0.005  4.72 :t: 0.061  <0.01 
(17.161)  (53.467) 
DMEM  4 x  l0  s SRBC  3.43 +_ 0.17  4.17 ±  0.15 
(2.689)  (14.774) 
* Reciprocal of hemolytic titer. 
PFC numbers expressed as 1°log PFC/spleen +  SE; figures within brackets equal geometrical mean. 
§ Culture supernatant, not purified. 
II The only antibody not cross-reacting with GRBC. 
¶ Not significant (P >  0.2). 
TABLE  VII 
Monoclonal Antibodies Non-Crossreactive with GRBC Can Potentiate the Anti-GRBC PFC Response 
When SRBC Is the Immunogen 
Percent 
PFC-anti-  P (vs.  PFC-anti-  P (vs.  P (vs.  anti- 
Inj I  Hit*  Inj II  con-  con- 
SRBC~  trol)  GRBC~  trol)  16-3)  GRBC 
PFC§ 
7-311  4096  4 ×  105 SRBC  4.27 ±  0.68  <0.1  3.82 +  0.15  <0.01  <0.005  40 _  8.5 
(18.460)  (6.614) 
10-2111  256  4 ×  105 SRBC  4.63 +  0.091  <0.05  4.13 ±  0.10  <0.001  <0.05  32 ±  3.7 
(42.491)  (13.382) 
16-311  ¶  8192  4 ×  105 SRBC  4.80 +  0.57  <0.01  4.46 ±  0.063  <0.001  46 ±  2.5 
(62.842)  (29.021) 
DMEM  4 ×  105 SRBC  3.73 ±  0.23  3.00 +  0.13  27 +  7.9 
(5.400)  (990) 
* Hemolytic titer. 
~: 1°log PFC/spleen +  SE; figures within brackets equal geometrical mean. 
§ GRBC-PFC/spleen ×  100 +  SE. 
SRBC-PFC/spleen 
H  Culture supernatants, not purified. 
¶ The only antibody preparation that is not cross-reactive with GRBC. 
HRBC,  but that SRBC  and  HRBC  cross react at the T  cell level (18-19). The  results 
obtained  with  HRBC  in  the  above  context  are  presented  in  Table  VIII.  Note  first 
that cross-reactivity at the B cell level is negligible as expected (< 1% in either direction 
as  indicated  in experiments  4-7).  Likewise,  anti-HRBC  responses were  never poten- 
tiated  when  IgM-anti-SRBC  antibodies  were  given  either  alone  (experiment  7), 
together  with  HRBC  (experiments  4-6),  or  when  the  antibodies  were  given  with 
SRBC  only  (experiments  5-7).  However,  a  striking potentiation  against  HRBC  was 1004  ENHANCEMENT  OF  THE  SHEEP  ERYTHROCYTE  RESPONSE  IN  MICE 
TABLe  VIII 
Enhancement of the Anti-HRBC Response 
Injection  Hh*  Injection II  PFC-anti-  Pcon-(VS'  PFC-anti-  P  (vs. 
I  SRBC:]:  trol)  HRBC:t:  control) 
256  4 ×  105 SRBC  ÷  3.50 ±  0.10  <0.001  4.15 ±  0.14  <0.025 
4 ×  105 HRBC  (3.144)  (14.095) 
4×  105 SRBC  ÷  2.13±0.19  3.50±0.16 
4 X  105 HRBC  (133)  (3.165) 
Experiment 1§  10-2111 
DMEM 
Experiment 2  10-21[[  256  4 x  105 SRBC  +  4.59 ±  0.10  <0.005  4.32 ±  0.13 
4 ×  105 HRBC  (39.159)  (20.837) 
DMEM  4 ×  105 SRBC  +  3.98 ±  0.097  3.81  ±  0.28 
4 ×  105 HRBC  (9.650)  (6.471) 
<0.2 
Experiment 3  10-2111  128  4 x  105 SRBC  +  4.82 ±  0.089  <0.05  4.21  +  0.16 
4 x  105 HRBC  (66.278)  (16.126) 
PBS  4 x  105 SRBC  +  4.20 ±  0.23  3.17 ±  0.34 
4 x  105 HRBC  (15.785)  (1.465) 
<0.05 
Experiment 4  7-3¶  4096  4 ×  l0  s SRBC  +  4.27 ±  0.10  <0. i  4.46 ±  0.11 
4 ×  i05 HRBC  (18.460)  (28.910) 
10-21¶  256  4 ×  105 SRBC  ÷  4.63 ±  0.091  <0.01  4.54 ±  0.89 
4 ×  105 HRBC  (42.491)  (34.745) 
16-3¶  8192  4 ×  105 SRBC  +  4.80 ±  0.057  <0.005  4.53 ±  0.066 
4 ×  105 HRBC  (62.842)  (33.889) 
DMEM  4 ×  105 SRBC  +  3.91  ±  0.29  4.24 +  0.076 
4 X  105 HRBC  (5.400)  (17.339) 
7-3¶  4096  4 ×  105 HRBC  2.27 ±  0.081  NS**  4.47 +  0.058 
(188)  (27.963) 
10-21¶  256  4 ×  105 HRBC  2.28 ±  0.16  NS  4.37 ±  0.18 
(192)  (23.228) 
16-3¶  8192  4 ×  105 HRBC  2,04 ±  0.24  NS  4.24 ±  0.08 
(110)  (I 7.393) 
DMEM  4 X  105 HRBC  2.47 ±  0.23  NS  4.45 ±  0.11 
(298)  (28.007) 
<0.2 
<0.05 
<0.025 
NS 
NS 
<0.1 
Experiment 5  10-2111  128  4 ×  105 HRBC  2.22 +  0.16  NS  4.20 __. 0.16 
(164)  (15.855) 
16-311  256  4 ×  105 HRBC  2.24 +  0.66  NS  4.28 +  0.076 
(174)  (19.025) 
IgM:[::l:  256  4 x  105 HRBC  2.25 ±  0.14  NS  4.24 +  0.042 
(178)  (17.391) 
PBS  4 ×  105 HRBC  2.00 ±  0.13  4.12 +  0.076 
(100)  (13.048) 
10-2111  128  4 x  105 SRBC  4.71  _. 0.044  <0.001  2.48 ±  0.38 
(5 I. 104)  (303) 
PBS  4 x  105 SRBC  3.93 +  0.12  2.79 +  0.099 
(8.588)  (617) 
NS 
<0.2 
<0.2 
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PFC-anti-  P (vs.  PFC-anti-  P  (vs.  Injection  Hit*  Injection II  con- 
I  SRBC:~  trol)  HRBC:~  control) 
Experiment 6  7-311  256  1 ×  10  ~ HRBC  2.23 ±  0.13  NS  3.00 ±  0.13  NS 
(168)  (990) 
10-21H  128  1 ×  105 HRBC  2.18 +  0.073  NS  2.90 ±  0.21  NS 
(152)  (788) 
PBS  1 ×  105 HRBC  2.33±0.11  3.16±0.17 
(214)  (1.438) 
7-31t  256  4 X  l0  s SRBC  4.42 ±  0.10  <0.2  1.88 ±  0.073  NS 
(26.202)  (76) 
10-2111  128  4 ×  105 SRBC  4.57 ±  0.063  <0.0025  2.27 ±  0.18  NS 
(37.562)  (186) 
PBS  4×  I05 SRBC  4.13±0.13  2.06±0.11 
(13.518)  (I15) 
Experiment 7  IgM:l::]:  1024  0  1.89 ±  0.073  NS  2.04 ±  0.15  NS 
(76)  (108) 
IgM  512  0  1.82 ±  0.073  NS  1.88 ±  0.12  NS 
(66)  (76) 
IgM  256  0  1.82 ±  0.073  NS  2.0 ±  0.13  NS 
(66)  (100) 
IgM  128  0  2.10 +  0.062  <0.001  1.82 +  0.073  NS 
(125)  (66) 
IgM  64  0  1.95 ±  0.11  NS  2.0 ±  0.045  NS 
(89)  (lOO) 
PBS  0  1.76 ±  0.06  2.0 2:0.13 
(57)  (10O) 
IgM~:~:  256  4 ×  10  ~ SRBC  5.54 ±  0.072  <0.001  2.16 ±  0.14  NS 
(122.395)  (143) 
PBS  4×  105 SRBC  4.31  ±0.12  2.41  ±0.13 
(20,749)  (255) 
* Reciprocal of hemolytic trier of the antibody preparations. 
:1: PFC numbers expressed as ~°log PFC/spleen :lz SE;  figures within brackets equal geometrical mean. 
§ This experiment was done with AKR mice. 
[I 19 S fraction of culture supernatants. 
¶ Culture supernatants, not purified. 
** Not significant (P >  0.2). 
~: 19 S fraction of serum from CBA/H mice immunized with SRBC, 
observed if anti-SRBC  IgM  antibodies  were  administered  into  mice  that  received 
SRBC and HRBC  (experiments 1-4). We could thus conclude that IgM-anti-SRBC 
antibodies with no cross-reacting properties to HRBC still can effectively potentiate 
the IgM response against this antigen if two requirements are fulfilled: the antigen in 
question  (HRBC)  has to be present  in  vivo, and  so does the antigen  (SRBC)  with 
which the IgM antibodies react. 
Discussion 
It  is  by  now  a  well-established  fact  that  IgM  antibodies,  if  administered  with 
antigen ofT-dependent nature, will frequently lead to an enhanced humoral antibody 
response against the immunogen (4, 6). This is particularly pronounced if care is taken 
to  use  proper  amounts  of immunogen  and  antibody  and  optimal  timing  between 1006  ENHANCEMENT  OF THE SHEEP ERYTHROCYTE RESPONSE IN MICE 
antibody and antigen administration (4, 6). Comparatively little is known about the 
actual  underlying mechanism(s)  of this  IgM  potentiation  of antibody-production, 
where antibody and antigen are administered in close connection in terms of time. 
The potentiation requires the presence of immunocompetent T  lymphocytes (6-8); 
that is, IgM can not replace T  helper cells for induction of antibody production. It is 
not  known,  however,  whether  the  IgM  antibodies  potentiate  the  presentation  of 
antigen to the T  cells, increase the numbers of specific T  helper cells, or make the 
actual activation of B  lymphocytes more efficient by simultaneous  activation of T 
lymphocytes. As IgM antibodies are supreme inducers of potentiation of this kind of 
humoral  antibody  response  compared  with  the  mostly  negative  impact  by  IgG 
antibodies  (4),  one would  deem  it  likely that  constant  region  features of the  IgM 
molecules are responsible for these differences. Speculations have been made as to a 
possible connection between receptors for aggregated IgM on T  helper cells and the 
observed IgM potentiation, but they remain to be proven. In addition, IgM antibodies 
have been reported to sometimes display an inherent ability to induce in the absence 
of immunogen a  highly potent antibody synthesis of IgM antibodies with the very 
same  antigen-binding specificity as  the  injected antibodies  (9).  Furthermore, poly- 
clonal activation of B cells by IgM antibodies alone has also been reported (8). This 
would  then  indicate that  variations in  the  antigen-binding,  idiotypic area of IgM 
antibodies  may  sometimes  endow  such  an  antibody  with  a  dramatic  capacity  to 
function as a powerful and sometimes selective antibody inducer, making interpreta- 
tions of earlier IgM  enhancement  data  very difficult. Other results  (10-12)  would 
indicate the constant  region of IgM as the most  relevant, because binding of IgM 
molecules to a particular group of epitopes on an antigen could be shown to lead to 
a  significant enhancement of the humoral response against other antigenic determi- 
nants simultaneously present on the immunogen. 
We have explored the ability of monoclonal or polyclonal IgM anti-SRBC  anti- 
bodies in the murine system to potentiate anti-SRBC antibody production in relation 
to the above findings as this antigenic system represents the most studied system in 
this regard. Our new approach was to use well-defined monoclonal IgM anti-SRBC 
antibodies  with  different antigen-combining specificity, produced  and  used  in  the 
same  strain  of mice,  CBA/H.  First,  we  demonstrated  that  the  ability  of either 
monoclonal  or  polyclonal  IgM  anti-SRBC  antibodies  to  potentiate  the  immune 
response against  low doses of SRBC  was  very similar when compared at  identical 
hemolytic titers. Thus, we find no evidence of variable region features contributing to 
potentiation in a quantitatively detectable manner. Second, using titration curves, we 
demonstrated that  there seemingly exists an optimal  amount  of IgM  which, when 
bound to the SRBC, allows maximal effect, and that the use of antibody concentra- 
tions above this titration point failed to further enhance the potentiation. We do not 
know, however, at what level this limitation lies. The ability of the IgM anti-SRBC 
antibodies  to  potentiate  the  response  against  low  doses  of SRBC  displayed  time 
kinetics in line with the view that the induction of anti-SRBC B cells was made more 
efficient in general, without having to consider the introduction of some new factor in 
the induction of antibody synthesis by the added IgM antibodies. An extensive series 
of experiments was then set up in various ways to explore whether IgM anti-SRBC 
antibodies  alone could  induce  IgM  anti-SRBC  antibody production as  previously 
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Our results using monoclonal or polyclonal IgM anti-SRBC antibodies here were 
uniformly negative. Furthermore, as the antibodies failed to change the background 
PFC  against  SRBC  and  another  antigen,  HRBC,  no  general,  polyclonal  B  cell 
activation could have occurred. The fact that not only monoclonal, but also polyclonal 
IgM anti-SRBC antibodies failed to enhance would argue against  monoclonal anti- 
body variability being responsible for discrepancies between our results and those of 
others. We thus feel confident that  in the present CBA/H anti-SRBC system IgM- 
anti-SRBC syngeneic antibody molecules fail to induce either specific IgM-anti-SRBC 
or  polyclonal  B  cell  activation.  This  would  suggest  that  the  previously  reported 
capacity of IgM antibodies to acutely induce intense antibody production with the 
same specificity in the absence of antigen (9) may be restricted to certain experimental 
conditions. 
Using monoclonal IgM-anti-SRBC that did or did not cross-react with GRBC, an 
antigen that extensively cross-reacts with SRBC at the epitope level, we could clearly 
demonstrate that the binding of IgM antibodies that do not cross-react with GRBC 
to epitopes on SRBC would cause the same degree of potentiation of the antibody 
response as cross-reacting IgM when measured against GRBC. In contrast, the same 
monoclonal antibodies failed altogether to potentiate either anti-SRBC  or -GRBC 
responses when GRBC was the immunogen used. These findings confirm the results 
in another system  (12), and  are to be expected if the constant-region class-specific 
features of IgM molecules are the decisive factors in the IgM induced potentiation of 
antibody responses. 
None of our anti-SRBC monoclonal antibodies were cross-reactive with HRBC as 
one  would  expect  from  the  very low  cross-reacting properties  of anti-SRBC  and 
-HRBC  antibodies  in  general  (for example,  see  experiment  4-7,  Table  VIII).  In 
agreement with the failure to bind HRBC, none of the anti-SRBC monoclonals could 
enhance the anti-HRBC production if given with SRBC alone or with HRBC alone. 
However, a  dramatic  impact  of enhancement was  noted when  SRBC  and  HRBC 
were given together with anti-SRBC antibodies, suggesting that the potentiated anti- 
SRBC response now could help the anti-HRBC response. The underlying mechanism 
of this finding is presently under scrutiny. As HRBC can cross-react with SRBC at 
the T  cell level (18-19), one may speculate that  the observed effect is specific and 
mediated by the potentiated induction ofT helper cells for SRBC, some of which also 
cross-react with HRBC. These HRBC-reactive T  cells could then, in the presence of 
HRBC, help B cells to produce anti-HRBC antibodies seen as the enhancement of 
HRBC-specific PFC  (Table VIII, experiments  1-4). Another possible mechanism  is 
that  an  increased antigen-antibody trapping in  the spleen caused by the IgM  (23) 
could  subsequently  lead  to  trapping  and  thereby  increased  immunogenicity of a 
second antigen, in this case HRBC (24). Experiments that will prove or disprove these 
assumptions, and that will more definitely define the mode of action of IgM in general 
in potentiating humoral antibody responses against T  dependent antigens have been 
initiated. 
Summary 
Monoclonal or polyclonal IgM-anti-SRBC  antibodies  were used  to enhance  the 
anti-SRBC PFC response in mice. For potentiation to occur, the IgM antibodies must 
always be presented with the antigen for which they have specificity. No enhancement 1008  ENHANCEMENT  OF THE SHEEP ERYTHROCYTE RESPONSE IN MICE 
of anti-SRBC response above control levels was noted with either antibodies alone or 
with antibodies used together with non-cross-reacting antigens. 
The  degree  of enhancement  was  independent  of whether  only  one  or  several 
different monoclonal IgM antibodies were used. Likewise, the fine specificity variation 
among the antibody clones failed to influence the anti-SRBC potentiation, which was 
shown to vary only with the amount of IgM bound to SRBC measured by hemolytic 
titers. 
The response against epitopes on the SRBC other than those the IgM recognized 
was also enhanced. This was determined by injecting SRBC and a  monoclonal anti- 
SRBC IgM that did not crossreact with GRBC into mice, and measuring the response 
against both antigens.  Normally SRBC and GRBC cross-react at the B cell level to 
-30%, and in this experiment they did so both in the control group and in the IgM 
group. 
Using antigens  that  only cross-react significantly at  the  T  cell  level  (SRBC  and 
HRBC), IgM-antibodies would only enhance the anti-HRBC response if SRBC and 
HRBC  were  inoculated  together.  No  anti-HRBC  potentiation  was  noted  when 
antibodies were injected alone or together with either SRBC or HRBC. 
The data indicate that the constant part of the IgM molecule is of major importance 
in  determining its  enhancing properties  in acute IgM-mediated potentiation of the 
immune responses. No evidence was obtained for a  decisive role of variable regions. 
Furthermore,  no general  B  cell  activating properties of either  mono- or polyclonal 
IgM-anti-SRBC antibodies could be demonstrated. 
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